Venture Map · Round
SpliceBio — Series A · €50M
Announced 2022-02-16 · Barcelona · Biotech / gene therapy
SpliceBio raised an oversubscribed €50M Series A for its protein-splicing platform, which uses engineered inteins from Princeton's Muir Lab to deliver genes too large for a single AAV vector; its lead programme targets Stargardt disease. UCB Ventures and Ysios Capital co-led, so no single lead is stated.
RoundSeries A
Amount€50M
LeadNot disclosed
Date2022-02-16
CityBarcelona
SectorBiotech / gene therapy
The company
Investors 6
AAsabys Partners
www.asabys.com
GGilde Healthcare
NNew Enterprise Associates
NNovartis Venture Fund
UCB Ventures
YYsios Capital
www.ysioscapital.com